Massive stroke drug study shows Real-World results
NCT ID NCT06707987
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a clot-dissolving drug called non-immunogenic staphylokinase in over 23,000 adults who had an acute ischemic stroke within the last 4.5 hours. The goal was to see how safe and effective the drug is in everyday hospital practice. Researchers measured how many patients had little or no disability 90 days after treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE ISCHEMIC STROKE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Federal Brain and Neurotechnology Center
Moscow, 117513, Russia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could muscle loss predict stroke recovery?
- Can a drug boost brain recovery after stroke?
- Can a blood Clot's inflammation predict stroke recovery?
- Can a new infusion drug boost stroke recovery?
- Can removing clots from tiny brain arteries boost stroke recovery?
- Could vague stroke symptoms delay lifesaving treatment?